Furthermore, we performed a multicenter, randomized, open-label, comparative study to investigate the safety and efficacy of transhepatic arterial administration of granulocyte-colony stimulating factor (G-CSF) mobilized autologous peripheral blood CD34-positive cells compared with standard therapy in patients with HCV-related decompensated liver cirrhosis [138]. The gene discussed is CSF3; the disease is cirrhosis of liver.